Lv4
558 积分 2022-05-11 加入
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
2天前
已完结
Discovery and preclinical evaluations of drug candidate DA-0157 capable of overcoming EGFR drug-resistant mutation C797S and EGFR/ALK co-mutations
2天前
已完结
[Expert consensus on clinical practice of EGFR exon20 insertion detection in non-small cell lung cancer in China (2024 edition)]
3天前
已完结
甲状腺结节和分化型甲状腺癌诊治指南
4天前
已完结
Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study
9天前
已完结
Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP)
10天前
已完结
Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study
10天前
已完结
Catalytic Lysine745 Targeting Strategy in Fourth-Generation EGFR Tyrosine Kinase Inhibitors to Address C797S Mutation Resistance
23天前
已完结
Hallmarks of Cancer: New Dimensions
23天前
已完结
Safety, Pharmacokinetics, and Efficacy of TY-9591 (Deuterated Osimertinib Derivative) in Advanced EGFR-mutated Non-Small Cell Lung Cancer: A Phase 1 Dose-Escalation and Dose-Expansion Study
1个月前
已完结
皖公网安备34019202002308
